🔗 Share this article

The initial novel therapies for gonorrhoea in a generation are being hailed as a "significant breakthrough" in the effort against increasingly resistant strains of the bacteria, according to health experts.

A Worldwide Challenge

Gonorrhoea infections are on the rise worldwide, with figures suggesting over 82 million instances per year. Particularly high rates are observed in Africa and countries within the World Health Organization's Western Pacific region, which encompasses Mongolia and China to New Zealand. Across England, cases have hit a record high, while infection numbers across Europe in 2023 were significantly elevated compared to figures for 2014.

“The approval of novel therapies for gonorrhoea is an critical and opportune step in the face of growing infection rates, increasing antimicrobial resistance and the extremely scarce treatment choices currently available.”

Public health authorities are particularly alarmed about the rise in antibiotic-resistant strains. The WHO has designated it as a "high-priority threat". Recent surveillance showed that the effectiveness of standard treatments like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

A Pair of Novel Drugs Secure Authorization

Zoliflodacin, alternatively called a brand name, was cleared by the American regulatory agency in December for use against gonorrhoea. This disease can lead to serious health problems, including the inability to conceive. Researchers hope that targeted use of this new drug will help slow the development of resistance.

Another new antibiotic, developed by the drugmaker GSK, also received approval in the same week. This treatment, which is also used to treat urinary tract infections, was proven in research to be effective against drug-resistant strains of the gonorrhoea bacteria.

A Novel Approach to Creation

This new treatment stemmed from a innovative non-profit model for antibiotic development. The charitable organization GARDP partnered with the pharmaceutical company Innoviva to bring it to fruition.

“This approval marks a significant shift in the management of multidrug-resistant gonorrhoea, which up to this point has been outpacing our drug pipeline.”

Clinical Trial Data and Worldwide Availability

Based on data detailed in a prominent scientific publication, zoliflodacin cured the vast majority of uncomplicated infections. This puts it on an similar efficacy with the current standard treatment, which combines two antibiotics. The research enrolled over 900 participants from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its development partnership, GARDP has the ability to make available and distribute the drug in a wide range of developing nations.

Clinicians directly involved have voiced hope. Having a one-pill regimen like this is described as a "game-changer" for public health efforts. This is considered vital to alleviate the strain of the disease for people and to stop the proliferation of highly drug-resistant gonorrhoea globally.